TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that it has submitted the updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include the…


Previous articleNuminus Wellness Inc. Reports Q1 2023 Results
Next articleBexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™